nezulcitinib   Click here for help

GtoPdb Ligand ID: 11304

Synonyms: example 1 [WO2020051105A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for this Janus kinase inhibitor was obtained from the WHO's special release of proposed INNs for COVID-related therapeutics that was published in October 2020, with the proposed INN being nezulcitinib. The structure is a match to example 1 as claimed in Theravance's 2020 patent WO2020051105A1. Analysis of Theravance's pipeline webpage and suggests that this is likely to be their clinical lead TD-0903, which they identify as a lung-selective JAK inhibitor, since TD-0903 had begun evaluation in COVID-19 patients. At the point of creating this entry (Nov 2020) there had been no formal name>structure disclosure. We will update this as further details become available.
In June 2021, Theravance announced that top-line results from patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation, showed no statistically significant difference between nezulcitinib and placebo groups in terms of primary or secondary outcomes.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 104.38
Molecular weight 527.3
XLogP 4.36
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCc1cc(O)ccc1c1ccc2c(c1)[nH]nc2c1nc2c([nH]1)C[C@H](N(C2)C(C)C)C(=O)N1CC(C1)N(C)C
Isomeric SMILES CCc1cc(O)ccc1c1ccc2c(c1)[nH]nc2c1nc2c([nH]1)C[C@H](N(C2)C(C)C)C(=O)N1CC(C1)N(C)C
InChI InChI=1S/C30H37N7O2/c1-6-18-11-21(38)8-10-22(18)19-7-9-23-24(12-19)33-34-28(23)29-31-25-13-27(37(17(2)3)16-26(25)32-29)30(39)36-14-20(15-36)35(4)5/h7-12,17,20,27,38H,6,13-16H2,1-5H3,(H,31,32)(H,33,34)/t27-/m0/s1
Immunopharmacology Comments
This is a Janus kinase inhibitor that is delivered locally to the lungs and is being investigated as a treatment for inflammatory lung diseases.